Misoprostol
- Generic Name
- Misoprostol
- Brand Names
- Arthrotec, Cytotec, Mifegymiso
- Drug Type
- Small Molecule
- Chemical Formula
- C22H38O5
- CAS Number
- 59122-46-2
- Unique Ingredient Identifier
- 0E43V0BB57
- Background
Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions. The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the strength and frequency of contractions and decrease cervical tone.
Misoprostol was granted FDA approval on 27 December 1988.
- Indication
Misoprostol is indicated as a tablet to reduce the risk of NSAID induced gastric ulcers but not duodenal ulcers in high risk patients. Misoprostol is also formulated in combination with diclofenac to treat symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcers. Misoprostol is used off label for the management of miscarriages, prevention of post partum hemorrhage, and is also used alone or in combination with mifepristone in other countries for first trimester abortions.
- Associated Conditions
- Gastric Ulcer, Incomplete Abortion, Missed Abortion, Postpartum Haemorrhage (PPH)
- Associated Therapies
- Induction of cervix ripening therapy, Medically induced abortion
Comparison of Two Regimens of Misoprostol for Second Trimester Medical Termination of Pregnancy
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2010-03-12
- Lead Sponsor
- Nilratan Sircar Medical College
- Target Recruit Count
- 185
- Registration Number
- NCT00401440
- Locations
- 🇮🇳
Department of Gynae & Obstetrics, Nilratan Sircar Medical College , Kolkata, Kolkata, West Bengal, India
A Randomized, Control Trial for Preinduction Cervical Ripening
- Conditions
- Labor, Induced
- First Posted Date
- 2006-10-29
- Last Posted Date
- 2008-01-16
- Target Recruit Count
- 540
- Registration Number
- NCT00393731
- Locations
- 🇺🇸
Lyndon B. Johnson Hospital, Houston, Texas, United States
Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia
- Conditions
- ContraceptionMenorrhagia
- Interventions
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 204
- Registration Number
- NCT00393198
Ripening Interventions: Prostaglandins vs EASI Catheter
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 80
- Registration Number
- NCT00383942
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
Trial of Cervical Ripening and Labor Induction Using Misoprostol With or Without Intravaginal Isosorbide Mononitrate
- Conditions
- Cervical Ripening
- Interventions
- First Posted Date
- 2006-09-11
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 156
- Registration Number
- NCT00374621
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Hysteroscopy and Misoprostol Project
- Conditions
- Uterine Hemorrhage
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2007-08-07
- Lead Sponsor
- Ullevaal University Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT00363389
- Locations
- 🇳🇴
Gynaecological Department, Ullevål University Hospital, Oslo, Norway
Comparison of Misoprostol and PGE2 Gel for Induction of Labour in Women With Premature Rupture of Membranes at Term
- Conditions
- Premature Rupture of Membranes at Term
- Interventions
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2010-03-25
- Lead Sponsor
- Nilratan Sircar Medical College
- Target Recruit Count
- 212
- Registration Number
- NCT00355966
- Locations
- 🇮🇳
NRS Medicl College,138 AJC Bose Road, Kolkata, West Bengal, India
Comparison of Misoprostol and Prostaglandin E2 (PGE2) Gel for Induction of Labour in Premature Rupture of Membranes at Term
- Conditions
- Premature Rupture of Membranes at Term
- Interventions
- First Posted Date
- 2006-07-21
- Last Posted Date
- 2015-07-22
- Lead Sponsor
- Nilratan Sircar Medical College
- Target Recruit Count
- 932
- Registration Number
- NCT00355303
- Locations
- 🇮🇳
Nilratan Sircar Medical College, 138,AJC Bose Road,, Kolkata, West Bengal, India
Safety and Efficacy Study of Misoprostol Vaginal Insert for Induction of Labour
- Conditions
- Labor InductionCervical Ripening
- Interventions
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2012-06-18
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT00346840
- Locations
- 🇬🇧
Northampton General Hospital, Northampton, United Kingdom
🇬🇧The Queen's Mother's Hospital, Yorkhill, Glasgow, United Kingdom
🇬🇧Liverpool Women's Hospital, Liverpool, United Kingdom
Oral Mifepristone and Buccal Misoprostol Administered Simultaneously for Abortion Through 63 Days Gestation
- Conditions
- Abortion, Induced
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2007-01-25
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 120
- Registration Number
- NCT00330993
- Locations
- 🇺🇸
Office of Family Planning Research, Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.